BioTelemetry, Inc. (BEAT) EPS Estimated At $0.31

July 14, 2018 - By Jimmy Baldridge

BioTelemetry, Inc. (NASDAQ:BEAT) LogoInvestors sentiment increased to 1.38 in 2018 Q1. Its up 0.50, from 0.88 in 2017Q4. It improved, as 21 investors sold BioTelemetry, Inc. shares while 53 reduced holdings. 34 funds opened positions while 68 raised stakes. 29.44 million shares or 6.24% more from 27.71 million shares in 2017Q4 were reported.
Logan Cap Incorporated stated it has 0.07% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Bridgeway Capital Management reported 0.01% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). 15,000 are held by Perkins Mngmt. Envestnet Asset Incorporated reported 5,712 shares or 0% of all its holdings. Glenmede Na holds 1.08 million shares. First Interstate Bancorp accumulated 0% or 629 shares. Tci Wealth reported 53 shares stake. Moreover, Lyons Wealth Mgmt Limited Com has 0.8% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 17,000 shares. Connecticut-based Thomson Horstmann And Bryant Incorporated has invested 0.6% in BioTelemetry, Inc. (NASDAQ:BEAT). First Tru Advisors Ltd Partnership owns 19,121 shares. Ubs Asset Mgmt Americas has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Rhumbline Advisers holds 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 72,768 shares. Alphamark Advsrs Llc invested in 30,377 shares or 0.4% of the stock. Ameriprise Financial holds 0% or 251,653 shares. Icon Advisers Incorporated holds 0.35% or 147,495 shares.

Analysts expect BioTelemetry, Inc. (NASDAQ:BEAT) to report $0.31 EPS on August, 14.They anticipate $0.08 EPS change or 34.78 % from last quarter’s $0.23 EPS. BEAT’s profit would be $10.17M giving it 39.72 P/E if the $0.31 EPS is correct. After having $0.39 EPS previously, BioTelemetry, Inc.’s analysts see -20.51 % EPS growth. The stock increased 0.92% or $0.45 during the last trading session, reaching $49.25. About 330,680 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 47.53% since July 14, 2017 and is uptrending. It has outperformed by 34.96% the S&P500.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry has $5400 highest and $41.0 lowest target. $47.50’s average target is -3.55% below currents $49.25 stock price. BioTelemetry had 2 analyst reports since February 23, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Friday, February 23 by Dougherty.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.62 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It currently has negative earnings. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

Another recent and important BioTelemetry, Inc. (NASDAQ:BEAT) news was published by Investorplace.com which published an article titled: “10 Small-Caps Leading the Market Rebound” on July 10, 2018.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: